Physician profile
Keith Andrew Aqua
NPI 1336105600
$473,397.42
in general payments reported to CMS, 2019-2025
36 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114K · 2020: $17K · 2021: $53K · 2022: $25K · 2023: $169K · 2024: $79K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $218K · Travel and Lodging: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $5,647 · Honoraria: $3,000 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $217,966.27 |
| Travel and Lodging | $26,191.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,685.00 |
| Food and Beverage | $5,647.44 |
| Honoraria | $3,000.00 |
| Education | $153.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $223,351.10 | 2022-2025 | Acessa Provu System, None |
| Abbvie INC. | $122,617.60 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Myovant Sciences INC. | $32,891.14 | 2021-2022 | |
| Lupin INC. | $31,851.90 | 2019-2021 | |
| Hologic Sales and Service, LLC | $19,272.26 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Sumitomo Pharma America, INC. | $14,688.82 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $11,437.98 | 2019-2021 | |
| Bolder Surgical, LLC | $8,366.27 | 2024 | Novasure |
| Intra-Sana Laboratories | $3,453.04 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $1,435.96 | 2020-2022 | |
| Royal Biologics, INC. | $1,100.00 | 2019 | |
| Channel Medsystems, INC. | $440.52 | 2023-2025 | |
| Astellas Pharma US INC | $432.05 | 2019-2025 | Veozah, Myrbetriq |
| Acelrx Pharmaceuticals, INC. | $400.00 | 2019 | |
| Mayne Pharma Commercial LLC | $293.95 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kvk-Tech, INC. | $249.63 | 2019-2021 | |
| Allergan, INC. | $225.44 | 2019-2020 | |
| Gynesonics, INC. | $150.57 | 2021-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Millicent US INC | $104.86 | 2020-2024 | Intrarosa, Femring |
| Exeltis, USA INC. | $97.21 | 2019-2024 | Slynd |
| Pfizer INC. | $87.12 | 2021-2023 | |
| Agile Therapeutics, INC. | $57.74 | 2021-2022 | |
| Novo Nordisk INC | $55.25 | 2019-2021 | |
| Momentis Surgical INC. | $43.82 | 2023 | Anovo Surgical System |
| Avion Pharmaceuticals | $41.07 | 2019-2020 | |
| Becton, Dickinson and Company | $37.57 | 2024 | Bd Onclarity |
| Biogen, INC. | $35.61 | 2025 | Zurzuvae |
| Covidien Lp | $33.03 | 2019 | |
| Lilly USA, LLC | $22.24 | 2025 | Zepbound |
| Daiichi Sankyo INC. | $22.04 | 2019 | |
| Organon LLC | $21.94 | 2024 | |
| Amgen INC. | $17.16 | 2025 | Evenity |
| Boston Scientific Corporation | $16.67 | 2021 | |
| Baxter Healthcare | $16.48 | 2025 | Perclot |
| Mycovia Pharmaceuticals, INC. | $14.80 | 2023 | Vivjoa |
| Amag Pharmaceuticals, INC. | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Aqua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.